Michael S Gordon1, Timothy W Kinlock2, Robert P Schwartz3, Kevin E O'Grady4, Terrence T Fitzgerald5, Frank J Vocci6. 1. Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States. Electronic address: mgordon@friendsresearch.org. 2. University of Baltimore, School of Criminal Justice, 10 W. Preston Street, Baltimore, MD 21201, United States. 3. Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States; University of Maryland School of Medicine, Department of Psychiatry, 701 West Pratt Street, Baltimore, MD 21201, United States. 4. Department of Psychology, University of Maryland, 4094 Campus Drive, College Park, MD 20742, United States. 5. Glenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD 21212, United States. 6. Friends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States.
Abstract
BACKGROUND: This study examined whether starting buprenorphine treatment prior to prison and after release from prison would be associated with better drug treatment outcomes and whether males and females responded differently to the combination of in-prison treatment and post-release service setting. METHODS: Study design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)×2 [Post-Release Service Setting Condition: Opioid Treatment: Program (OTP) vs. Community Health Center (CHC)]×2 (Gender) factorial design. The trial was conducted between September 2008 and July 2012. Follow-up assessments were completed in 2014. Participants were recruited from two Baltimore pre-release prisons (one for men and one for women). Adult pre-release prisoners who were heroin-dependent during the year prior to incarceration were eligible. Post-release assessments were conducted at 1, 3, 6, and 12-month following prison release. RESULTS: Participants (N=211) in the in-prison treatment condition effect had a higher mean number of days of community buprenorphine treatment compared to the condition in which participants initiated medication after release (P=0.005). However, there were no statistically significant hypothesized effects for the in-prison treatment condition in terms of: days of heroin use and crime, and opioid and cocaine positive urine screening test results (all Ps>0.14) and no statistically significant hypothesized gender effects (all Ps>0.18). CONCLUSIONS: Although initiating buprenorphine treatment in prison compared to after-release was associated with more days receiving buprenorphine treatment in the designated community treatment program during the 12-months post-release assessment, it was not associated with superior outcomes in terms of heroin and cocaine use and criminal behavior.
RCT Entities:
BACKGROUND: This study examined whether starting buprenorphine treatment prior to prison and after release from prison would be associated with better drug treatment outcomes and whether males and females responded differently to the combination of in-prison treatment and post-release service setting. METHODS: Study design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)×2 [Post-Release Service Setting Condition: Opioid Treatment: Program (OTP) vs. Community Health Center (CHC)]×2 (Gender) factorial design. The trial was conducted between September 2008 and July 2012. Follow-up assessments were completed in 2014. Participants were recruited from two Baltimore pre-release prisons (one for men and one for women). Adult pre-release prisoners who were heroin-dependent during the year prior to incarceration were eligible. Post-release assessments were conducted at 1, 3, 6, and 12-month following prison release. RESULTS:Participants (N=211) in the in-prison treatment condition effect had a higher mean number of days of community buprenorphine treatment compared to the condition in which participants initiated medication after release (P=0.005). However, there were no statistically significant hypothesized effects for the in-prison treatment condition in terms of: days of heroin use and crime, and opioid and cocaine positive urine screening test results (all Ps>0.14) and no statistically significant hypothesized gender effects (all Ps>0.18). CONCLUSIONS: Although initiating buprenorphine treatment in prison compared to after-release was associated with more days receiving buprenorphine treatment in the designated community treatment program during the 12-months post-release assessment, it was not associated with superior outcomes in terms of heroin and cocaine use and criminal behavior.
Authors: Nabarun Dasgupta; Elise J Bailey; Theodore Cicero; James Inciardi; Mark Parrino; Andrew Rosenblum; Richard C Dart Journal: Pain Med Date: 2010-06-08 Impact factor: 3.750
Authors: John Strang; Michael Gossop; Joan Heuston; John Green; Christopher Whiteley; Anthony Maden Journal: Addiction Date: 2006-08 Impact factor: 6.526
Authors: Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Michael S Gordon; Thomas R Blue; Kathryn Couvillion; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci Journal: Drug Alcohol Depend Date: 2018-05-12 Impact factor: 4.492
Authors: William E Soares; Donna Wilson; Michael S Gordon; Joshua D Lee; Edward V Nunes; Charles P O'Brien; Milvin Shroff; Peter D Friedmann Journal: Drug Alcohol Depend Date: 2018-12-03 Impact factor: 4.492
Authors: Kelly E Moore; Walter Roberts; Holly H Reid; Kathryn M Z Smith; Lindsay M S Oberleitner; Sherry A McKee Journal: J Subst Abuse Treat Date: 2018-12-15
Authors: Amy J Kennedy; Charles B Wessel; Rebecca Levine; Kendall Downer; Megan Raymond; Deborah Osakue; Iman Hassan; Jessica S Merlin; Jane M Liebschutz Journal: J Gen Intern Med Date: 2021-01-19 Impact factor: 5.128
Authors: Michael S Gordon; Shannon Gwin Mitchell; Thomas R Blue; Frank J Vocci; Marc J Fishman; Sean M Murphy; Kathy Couvillion; Kelly Maher; Danielle Ryan; Kevin Wenzel; Martha L Danner; Daniel K Jarvis Journal: J Subst Abuse Treat Date: 2020-12-11